NiCord: Additional Phase I/II data
Additional data from an open-label, U.S. Phase I/II trial in 11 patients with high-risk hematological malignancies evaluating co-transplantation of NiCord with an unmanipulated graft of umbilical cord blood (UCB) following myeloablative conditioning showed that 8 patients engrafted with NiCord and 2 patients engrafted with unmanipulated UCB. There was 1 primary graft failure. In patients engrafting with NiCord, median time to neutrophil engraftment was 10.5 days. The estimated 100-day treatment-related mortality rate was 10%. At a median follow-up of 8 months, the progression-free survival (PFS) and overall survival (OS) rates were both 90%. Grade 1/2 acute GvHD occurred in 3 patients and there were no cases of grade 3/4 acute GvHD. Data were presented at the BMT Tandem Meetings in Salt Lake City. ...